| |
Today's new medicines are usually the result of collaborations between multi-skilled teams involved in different parts of the drug life cycle. Modern Pharma or Biotech companies often partner with companies who specialize in these diverse activities including: cutting-edge research, medicinal chemistry and biotechnology, process development, production, validation and regulatory approval for both API and Drug Product. Rarely are these conducted by just one company. However Shasun has the ability to offer a wide range of these specialist activities thus allowing the innovative drug company to reach the market quicker and more cost effectively.
Shasun is engaged in the manufacture of active pharmaceutical ingredients and drug products with a significant presence in the anti-inflammatory and anti-ulcerative therapeutic groups. In addition, the company has recently strengthened its offering in contract research, custom synthesis, contract manufacturing and contract formulation services through its acquisition of Rhodia Pharma Solutions and offers services and products to clients in US, Europe and Asia.
Today Shasun exports products to countries across Europe, North America and others and a wide range of customers from the smallest Biotech to most of the world's largest Pharmaceutical giants.
Shasun employs more than 1400 people in India, the UK and the US. Headquartered in Chennai ( India), Shasun operates world-class API facilities at Cuddalore and Puducherry in South India and Dudley in UK and Annan in Scottland. In the last few years Shasun has added a state-of-the-art research center in Chennai and a world class solid oral dosage formulation facility in Puducherry.
Shasun is publicly-held and listed on the National Stock Exchange and the Bombay Stock Exchange in India. |
